AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Bilfinger SE

Investor Presentation Nov 17, 2025

64_rns_2025-11-17_8692c341-e904-4bf7-95a7-a3096c553613.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

{0}------------------------------------------------

Q3 2025 Results

November 13, 2025 Dr. Thomas Schulz, Group CEO

Matti Jäkel, Group CFO

{1}------------------------------------------------

Highlights | Q3 2025

Stable development

in a volatile market

+1% / org. 0%

Orders Received

€ 1,360 million

+8% / org. +7%

Revenue

€ 1,384 million

5.8%

EBITA margin

from 6.0%

€ 1.47

Earnings per share

from € 1.45

€ 71 million

Free Cash Flow

from € 55 million

Updated Outlook

Revenue € 5.3 – 5.5 bn EBITA margin 5.4 – 5.6 %

New mid-term targets

Capital Markets Day

Dec 2, 2025

{2}------------------------------------------------

ESG Topics

Safety

TRIF: Total Recordable Incident Frequency

[based on 1 million working hours ]

LTIF: Lost Time Injury Frequency

[based on 1 million working hours ]

{3}------------------------------------------------

Industry Development

Production Index 1) Outsourcing Bilfing jer
Base year 2019 I Europe, Middle East and North America Potential Revenue Share 2) Demand
150 Chemicals & Petrochemicals Significant regional differences in expected growth $\Box$ 23% $\Rightarrow$
140 Energy
130 Increasing demand for storage 23%
120 and transmission
110 Oil & Gas Strong LNG demand offsetting ~ 20% ~
100 lower refinery demand 20 /0
90 Pharma & Biopharma 1
80 — Growth driver: Localization, reduced time to market 13% $\langle \lambda \rangle$
2019 2020 2021 2022 2023 2024 2025E 2026E reduced lille to market ·

1) Includes content supplied by S&P Global Market Intelligence; Copyright © S&P Global Market Intelligence, 2025. All rights reserved. 2) % of Group revenues YTD/25, 21% in adjacent industries

{4}------------------------------------------------

Selected Orders Received

Adjacent Industries

Semiconductor Manufacturer Germany Technologies

Prefabrication and installation of the wastewater treatment system for resource-efficient chip production

Energy

E.ON Sweden E&M Europe

Prefabrication and assembly of heat accumulator to increase reliability and sustainability of district heating supply

Oil & Gas

KNPC Kuwait E&M International

Comprehensive front-end engineering design services for new North Oil Pier, enhancing operational efficiency

{5}------------------------------------------------

Innovation: Bilfinger DRIS 2.0

Efficient inspection under insulation during routine operations

  • Moisture causes ice on pipes and equipment where insulation is defect or missing
  • Inspection and renewal of insulation is only possible during plant shutdown to avoid corrosion
  • Tight turnaround schedules

  • Portable system to reduce dew point around pipes, preventing formation of moisture and ice

  • Safe removal of insulation at very low temperatures without risk of corrosion
  • De-insulation and inspection can be carried out while equipment is live

{6}------------------------------------------------

Bilfinger Demand

Opportunity pipeline [indexed on July 2023]

Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep

Orders received [€ million]

Order backlog [€ million]

Q3 Development

Orders received

  • Stable demand in a volatile market environment
  • Larger order intake in the Chemical, Semiconductor production, and Hydrogen production sectors

{7}------------------------------------------------

Group | Revenue Development

Revenue [€ million] | Book-to-Bill

Change abs. org.
E&M Europe +5% +2%
E&M International +8% +14%
Technologies +24% +25%

Revenue split [%]

Q3 Development

  • Growth in all segments
  • Growth in the Oil & Gas, Energy, and Pharma & Biopharma industries
  • Decline in Chemicals & Petrochemicals

{8}------------------------------------------------

Group | Performance

Revenue [€ million] | Book-to-Bill [ratio]

  • Growth in all segments
  • Growth in the Oil & Gas, Energy, and Pharma & Biopharma industries
  • Decline in Chemicals & Petrochemicals

Gross profit | SG&A [€ million, %]

  • Gross profit at prior year level
  • Improvement in SG&A ratio

EBITA [€ million, %]

▪ Margin slightly below prior-year quarter, as expected

-3 1 -1 0 -1

∆ abs. / org.

{9}------------------------------------------------

Segment E&M Europe | Performance

  • Organic growth mainly from Oil & Gas industry
  • Chemicals & Petrochemicals industry remains challenging, especially in Germany

Orders received [€ million] Revenue [€ million] | Book-to-Bill [ratio]

  • Growth from Energy and Oil & Gas industries
  • Chemicals & Petrochemicals industry remains challenging

EBITA [€ million, %]

  • Profitability continues to improve over the course of the year due to efficiency gains
  • Margin below prior-year quarter

1) Restatement of 2024 figures due to change in allocation of entities: Orders received +2; revenue +2; EBITA 0

{10}------------------------------------------------

Segment E&M International | Performance

  • Growth compared to previous year due to a mix of framework additions as well as contract awards
  • US market remains cautious due to political uncertainties
  • Middle East with growth in Oil & Gas industry

Orders received [€ million] Revenue [€ million] | Book-to-Bill [ratio]

  • Revenue growth predominantly in Middle East region as well as in North America in the Maintenance business
  • Oil & Gas industry with growth rates

EBITA [€ million, %]

  • In line with expectations and outlook
  • Both regions are contributing

1) Restatement of 2024 figures due to change in allocation of entities: Orders received -2; revenue -2; EBITA 0

{11}------------------------------------------------

Segment Technologies | Performance

  • Continue to benefit from investment cycle in Pharma & Biopharma
  • Slight growth in the nuclear and energy transition business lines

Orders received [€ million] Revenue [€ million] | Book-to-Bill [ratio]

  • Growth driven by strong order intake in previous quarters
  • Delays in energy transition business line

EBITA [€ million, %]

  • Margin improvement due to improved Operational Excellence
  • Improvement of +90 bps in comparison to Q3/24

{12}------------------------------------------------

Group | Net Profit and Earnings per Share

Q3 Development

Financial result

In line with previous year

Taxes

Tax rate increased from 21% to 25%

Net profit / Earnings per share

■ 1% increase year-over-year

{13}------------------------------------------------

Group | Cash flow and Working Capital

Operating cash flow [€ million] Free cash flow [€ million] Net Trade Assets / Revenue [%]

▪ Continued efficient working capital management

▪ Positive contributions from all segments ▪ Improved receivables position in relation to revenue

{14}------------------------------------------------

Group | Net Liquidity and Leverage

Net liquidity [€ million] Net debt / EBITDA [ratio]1)

Leverage < 2.0

1) S&P definition

{15}------------------------------------------------

Segments | Outlook

[€ million, %] Actual
YTD 2024
Actual
YTD 2025
Previous
Outlook
FY 2025
Updated
Outlook
FY 2025
Revenue 2,556 2,740 3,500 to
4,000
3,600 to
3,900
E&M Europe1) EBITA
margin
5.8% 5.7% 5.8 to
6.4%
5.8 to
6.2%
Revenue 516 551 700 to 800 700 to 800
E&M
International2)
EBITA
margin
-0.4% 3.1% 2.0 to 4.0% 2.0 to 4.0%
Revenue 538 629 750 to 850 800 to 850
Technologies EBITA
margin
5.5% 6.6% 6.3 to 6.8% 6.8 to 7.2%
Reconciliation Revenue 65 85 80 to 130 90 to 120
Group EBITA 14 -4 -20 to 5 -10 to 5

1) Restatement of 2024 figures due to change in allocation of entities: revenue +2; EBITA +0

2) Restatement of 2024 figures due to change in allocation of entities: revenue -2; EBITA -0

{16}------------------------------------------------

Group | Outlook

[€ million, %] Actual
YTD 2024
Actual
YTD 2025
Previous
Outlook
FY 2025
Updated
Outlook
FY 2025
Mid-term targets
2025-2027
Revenue 3,676 4,004 5,100 to 5,700 5,300 to 5,500 4 - 5% CAGR
EBITA margin 5.2% 5.3% 5.2 to 5.8% 5.4 to 5.6% 6 - 7%
Free cash flow 105 1) 233 210 to 270 1) 2) 300 to 360 1) 2) > 80% Cash
Conversion

1) Including a mid double-digit million amount cash-inflow due to completion of a legal proceeding

2) Including ~ €30 million special items cash-out integration expenses acquired business and Efficiency Program

17 Bilfinger | Q3 2025 Results | November 13, 2025

{17}------------------------------------------------

Highlights | Q3 2025

Stable development

in a volatile market

+1% / org. 0%

Orders Received

€ 1,360 million

+8% / org. +7%

Revenue

€ 1,384 million

5.8%

EBITA margin

from 6.0%

€ 1.47

Earnings per share

from € 1.45

€ 71 million

Free Cash Flow

from € 55 million

Updated Outlook

Revenue € 5.3 – 5.5 bn EBITA margin 5.4 – 5.6 %

New mid-term targets

Capital Markets Day

Dec 2, 2025

{18}------------------------------------------------

Quarterly Statement Q3 2025

Financial Backup

{19}------------------------------------------------

Segment Development Q3 2025

Reconciliation Group

Ket oncilial ion Gre Jup _
E&I M Euro pe E&M Internat tional Tec hnolog ies HQ/C onsolida
Other
ation / Othe r Opera tions Group
[€ million] Q3/25 Q3/24 $\Delta$ in % Q3/25 Q3/24 $\Delta$ in $\%$ Q3/25 Q3/24 Δ in % Q3/25 Q3/24 Δ in % Q3/25 Q3/24 $\Delta$ in $\%$ Q3/25 Q3/24 $\Delta$ in $\%$
Orders received 894 860 +4% 192 175 +10% 270 268 0% -23 -19 - 28 59 -53% 1,360 1,344 +1%
Order backlog 2,887 2,563 +13% 576 550 +5% 897 877 +2% -10 -15 - 62 133 -54% 4,412 4,109 +7%
Revenue 936 893 +5% 182 169 +8% 239 192 +24% -22 -9 - 49 39 +27% 1,384 1,284 +8%
SG&A -50 -53 -6% -14 -12 +23% -13 -12 +10% -1 0 - -2 -2 +11% -80 -78 +2%
EBITDA 79 78 +2% 10 -7 - 21 15 +36% -3 13 - 5 7 -29% 111 106 +5%
EBITDA margin 8.5% 8.7% 5.3% -4.2% 8.8% 8.1% - - 10.1% 18.1% 8.1% 8.3%
EBITA 57 56 +2% 7 -9 - 19 13 +42% -6 10 - 4 7 -32% 81 76 +6%
EBITA margin 6.1% 6.3% 4.0% -5.4% 7.8% 6.9% - - 9.1% 16.9% 5.8% 6.0%
Special items
EBITA
0 -3 - 0 0 - 0 0 - 0 0 - 0 0 - -1 -3 -
Amortization -2 0 - 0 0 - 0 0 - 0 0 - 0 0 - -2 0 -
Depreciation -22 -22 - -2 -2 - -2 -2 - -3 -3 - -1 0 - -31 -30 -
Investments in P, P & E 9 8 +3% 1 1 +5% 1 1 +47% 1 1 +57% 0 0 - 12 11 +9%
Increase in right-
of-use assets
7 6 +10% 2 1 +179% 1 1 -50% 1 2 -39% 0 1 - 10 11 -5%
Employees 22,949 22,916 0% 5,711 5,404 +6% 1,703 1,702 0% 579 539 +7% 740 733 +1% 31,682 31,294 +1%

{20}------------------------------------------------

Segment Development YTD 2025

Red concilia tion Gr oup
E&I M Europ )e E&M I nternati ional Tec hnolog ies HQ/C Consolid
Other
ation / Othe er Opera tions Group
[€ million] YTD/25 YTD/24 Δin % YTD/25 YTD/24 Δ in % YTD/25 YTD/24 Δin % YTD/25 YTD/24 Δ in % YTD/25 YTD/24 Δin % YTD/25 YTD/24 Δ in %
Orders received 2,962 2,698 +10% 632 527 +20% 730 688 +6% -59 -55 - 139 139 0% 4,405 3,997 +10%
Order backlog 2,887 2,563 +13% 576 550 +5% 897 877 +2% -10 -15 - 62 133 -54% 4,412 4,109 +7%
Revenue 2,740 2,556 +7% 551 516 +7% 629 538 +17% -73 -54 - 158 119 +32% 4,004 3,676 +9%
SG&A -157 -146 +8% -41 -35 +14% -40 -37 +8% -9 -13 - -6 -6 +10% -253 -237 +6%
EBITDA 225 209 +8% 24 4 +447% 48 36 +35% -16 5 - 23 19 +20% 304 273 +11%
EBITDA margin 8.2% 8.2% 4.4% 0.9% 7.7% 6.7% - - 14.3% 15.7% 7.6% 7.4%
EBITA 157 148 +6% 17 -2 - 42 29 +41% -25 -3 - 21 17 +22% 212 190 +12%
EBITA margin 5.7% 5.8% 3.1% -0.4% 6.6% 5.5% - - 13.3% 14.5% 5.3% 5.2%
Special items
EBITA
-2 6 - 0 0 - 0 0 - 1 0 - 0 0 - -1 7 -
Amortization -5 -1 - 0 0 - 0 0 - 0 0 - 0 0 - -5 -1 -
Depreciation -67 -60 - -7 -6 - -7 -7 - -9 -9 - -1 -1 - -92 -83 -
Investments in P, P & E 28 35 -19% 5 3 +57% 2 2 -2% 3 2 +100% 2 1 +90% 41 43 -5%
Increase in right-
of-use assets
22 18 +20% 3 4 -20% 1 3 -57% 8 3 +157% 0 1 -54% 34 28 +20%
Employees 22,949 22,916 0% 5,711 5,404 +6% 1,703 1,702 0% 579 539 +7% 740 733 +1% 31,682 31,294 +1%

{21}------------------------------------------------

Revenue Split

E&M Europe E&M International Technologies Group
YTD/25 YTD/24 YTD/25 YTD/24 YTD/25 YTD/24 YTD/25 YTD/24
Chemical & Petrochemical 33% 34% 8% 11% 2% 10% 23% 25%
Energy 18% 16% 14% 15% 34% 34% 23% 22%
Industry Split Oil & Gas 24% 22% 19% 14% 6% 3% 20% 17%
Pharma & Biopharma 6% 7% 0% 0% 55% 48% 13% 12%
Adjacent Industries 19% 21% 59% 60% 3% 5% 21% 24%
Contract Split Frame and service
contracts
66% 73% 78% 72% 1% 1% 57% 62%
Projects 34% 27% 22% 28% 99% 99% 43% 38%

{22}------------------------------------------------

Profit and Loss Statement

[€ million] Q3/25 Q3/24 ∆ in % YTD/25 YTD/24 ∆ in %
Revenue 1,384.1 1,283.8 +8% 4,004.4 3,675.6 +9%
Gross
profit
156.2 157.8 -1% 452.9 409.1 +11%
Selling and administrative expenses -80.2 -78.5 +2% -252.8 -237.4 +6%
Impairment
losses and reversal of impairment losses (as per IFRS 9)
-0.5 0.1 - -2.0 0.3 -
Other operating income and expense 1.7 -4.6 - 3.0 13.1 -77%
Income from
investments accounted for using the equity method
2.0 1.4 +47% 5.4 3.8 +42%
Earnings before interest
and taxes (EBIT)
79.1 76.2 +4% 206.6 188.9 +9%
Amortization of int. assets from acquisitions and
goodwill impairments (IFRS 3)
-1.7 -0.3 - -5.2 -0.8 -
Earnings before interest, taxes and amortization of intangible assets (EBITA) 80.8 76.4 +6% 211.8 189.7 +12%
Special items in EBITA
1
-0.7 -2.7 - -1.4 6.6 -
Depreciation PP&E 30.7 29.6 +3% 92.3 83.5 +11%
thereof depreciation of right-of-use assets from leases 16.0 15.7 +2% 49.3 44.0 +12%
Earnings before interest, taxes, depreciation and amortization (EBITDA) 111.5 106.1 +5% 304.0 273.2 +11%
Financial result -4.9 -5.4 -10% -14.2 -16.0 -11%
Earnings before taxes (EBT) 74.3 70.8 +5% 192.4 172.9 +11%
Income taxes -18.5 -14.8 +25% -53.1 -42.4 +25%
Earnings after taxes EAT (continuing operations) 55.8 56.0 0% 139.3 130.5 +7%
Earnings after taxes EAT (discontinued operations) 0.0 0.3 - -0.2 1.6 -
Minority interests -1.2 -1.8 - -5.3 -4.5 -
Net profit 54.6 54.6 0% 133.8 127.6 +5%
Earnings per share (in €) 1.47 1.45 +1% 3.59 3.40 +6%
For information: adjusted Net profit 54.8 52.1 +5% 139.9 117.4 +19%
Adjusted Earnings per share (in €) 1.48 1.39 +6% 3.76 3.13 +20%
1
Special items
EBITA [in € million]
Q3/25
Badwill / Add. gain from PPA 2
Integration of acquisition 0
M&A, Others -3
Total -1

{23}------------------------------------------------

Consolidated Balance Sheet: Assets

[€ million] 9/30/25 6/30/25 $\Delta$ in % 9/30/25 12/31/24 $\Delta$ in %
Non-current assets 1,382.7 1,396.7 -1% 1,382.7 1,399.7 -1%
Intangible assets 822.2 ( 823.7 0% 822.2 813.8 +1%
Property, plant and equipment 280.9 284.8 -1% 280.9 287.1 -2%
Right of use assets from leases 178.2 182.5 -2% 178.2 188.4 -5%
Investments accounted for using the equity method 14.6 14.9 -2% 14.6 16.7 -12%
Other financial assets 6.4 6.5 -1% 6.4 6.2 +2%
Deferred taxes 80.4 84.2 -5% 80.4 87.4 -8%
Current assets 2,076.5 2,064.2 +1% 2,076.5 2,063.8 +1%
Inventories 117.6 116.0 +1% 117.6 115.1 +2%
Receivables and other financial assets 1,362.9 1,392.6 -2% 1,362.9 1,397.0 -2%
Current tax assets 22.4 12.3 +83% 22.4 10.6 +111%
Other assets 105.1 113.1 -7% 105.1 76.0 +38%
Securities 0.0 0.0 - 0.0 0.0 -
Marketable securities 0.0 0.0 - 0.0 0.0 -
Cash and cash equivalents 468.6 430.2 +9% 468.6 465.0 +1%
Assets classified as held for sale 0.0 0.0 - 0.0 0.0 -
Total 3,459.2 3,460.8 0% 3,459.2 3,463.5 0%

Goodwill decreased to €802 million (6/25: €803 million)

{24}------------------------------------------------

Consolidated Balance Sheet: Equity & Liabilities

[€ million] 9/30/25 6/30/25 $\Delta$ in % 9/30/25 12/31/24 $\Delta$ in %
Equity 1,308.6( 1,258.5 +4% 1,308.6 1,311.3 0%
Equity attributable to shareholders of Bilfinger SE 1,298.2 1,249.6 +4% 1,298.2 1,300.9 0%
Attributable to minority interests 10.3 8.8 +17% 10.3 10.4 0%
Non-current liabilities 481.8 489.7 -2% 481.8 631.5 -24%
Provisions for pensions and other obligations 249.3 251.1 -1% 249.3 266.2 -6%
Other provisions 23.0 23.6 -3% 23.0 24.8 -7%
Financial debt 186.8 191.3 -2% 186.8 317.3 -41%
Other liabilities 0.5 1.0 -53% 0.5 1.4 -65%
Deferred taxes 22.3 22.6 -1% 22.3 21.9 +2%
Current liabilities 1,668.8 1,712.7 -3% 1,668.8 1,520.7 +10%
Current tax liabilities 48.7 36.9 +32% 48.7 35.4 +38%
Other provisions 153.2 152.3 +1% 153.2 167.8 -9%
Financial debt 179.1 177.7 +1% 179.1 59.3 +202%
Trade and other payables 1,022.7 1,056.9 -3% 1,022.7 1,000.5 +2%
Other liabilities 265.2 288.9 -8% 265.2 257.8 +3%
Liabilities classified as held for sale 0.0 0.0 - 0.0 0.0 -
Total 3,459.2 3,460.8 0% 3,459.2 3,463.5 0%

1 Equity ratio increased to 38% (6/30/25: 36%)

{25}------------------------------------------------

Net Liquidity | Cash Flow Development Excluding IFRS 16

Net Trade Assets / DSO / DPO

Net liquidity1) [€ million] Cash flow development year-to-date excl. IFRS 16 [€ million]

Q3 2025
incl. IFRS
16
IFRS 16
impacts
Q3 2025
excl. IFRS
16
Q3 2024
excl. IFRS
16
EBITA 212 212 190
Depreciation 92 -49 43 39
Change in NWC 14 14 -111
Other non-cash income
/ expenses
-4 -4 0
Interest received 13 13 21
Income tax
payments
-44 -44 -26
Change in non-current
assets / liabilities
-10 -10 -5
Others
2)
-4 -7 -11 -16
Operating CF 269 213 92
Net CAPEX -36 -36 -40
Free CF 233 177 52
Proceeds/Investments financial assets -24 -24 -14
Share buyback program -38 -38 0
Changes
in marketable
securities
0 0 190
Dividends -89 -89 -67
Change in financial debt -50 50 0 -250
Interest paid -16 6 -10 -20
FX / other / DiscOp -12 -12 -10
Change in Cash 4 4 -119

1) Including IFRS 16 leases | 2) Gains / losses from disposal of non-current assets / Income from investments accounted for using the equity method / Dividends received

{26}------------------------------------------------

Consolidated Statement of Cash Flows [1/2]

[€ million] Q3/25 Q3/24 $\Delta$ in % YTD/25 YTD/24 $\Delta$ in %
EBITDA 111.5 106.1 +5% 304.0 273.2 +11%
Change in advance payments received -40.2 27.9 - -35.7 40.9 -
Change in trade receivables 6.2 40.0 -85% 3.9 -18.7 -
Change in trade payables and advance payments made 22.8 -66.2 - 80.9 -13.4 -
Change in net trade assets -11.3 1.7 - 49.1 8.8 +456%
Change in current provisions 0.8 -3.0 - -11.0 -27.2 -
Change in other current assets (including other inventories) and liabilities -9.4 -34.0 - -24.0 -92.5 -
Change in working capital -19.8 -35.3 - 14.1 -110.9 -
Change in non-current assets and liabilities 2.1 -5.1 - -9.4 -4.9 -
Gains / losses from disposal of non-current assets -2.3 -0.1 - -5.1 -4.6 -
Income from investments accounted for using the equity method -2.0 -1.4 - -5.4 -3.8 -
Dividends received 2.6 0.2 >+999% 6.4 1.7 +272%
Interest received 4.7 4.8 -1% 13.2 20.6 -36%
Income tax payments -13.9 -3.5 - -43.9 -26.5 -
Other non-cash income / expense -2.4 0.0 - -4.3 0.0 -
Operating cash flow (OCF) 80.4 65.7 +22% 269.4 144.7 +86%
Investments in property, plant and equipment and intangible assets -12.3 -11.3 - -40.9 -43.2 -
Payments received from the disposal of P, P & E and intangible assets 2.6 0.3 +668% 4.5 3.2 +39%
Net cash outflow for P, P & E and intangible assets (net capex) -9.8 -10.9 - -36.4 -40.0 -
Free cash flow (FCF) 70.7 54.7 +29% 233.0 104.8 +122%
thereof special items in free cash flow -7.0 -4.3 _ -17.8 -25.3 _

Thereof restructuring - €1 million, integration costs - €4 million and M&A - €2 million

{27}------------------------------------------------

Consolidated Statement of Cash Flows [2/2]

[€ million] Q3/25 Q3/24 $\Delta$ in % YTD/25 YTD/24 $\Delta$ in %
Free Cash Flow (FCF) [carry over] 70.7 54.7 29% 233.0 104.8 122%
Proceeds from / payments made for the disposal of financial assets 0.0 0.0 - 0.6 -0.8 -
Investments in financial assets 0.01 -5.51 _ -24.5 -13.5 -
Changes in marketable securities 0.0 0.0 - 0.0 190.5 -
- Share buyback -13.92 0.0 - -38.2 0.0 -
- Dividends 0.0 0.0 - -96.7 -73.0 -
- Changes in ownership interest without change in control 0.0 -0.7 - 0.0 -0.7 -
- Borrowing 0.0 0.0 - 0.0 0.0 -
- Repayment of financial debt -16.8 -16.4 - -50.0 -297.1 -
- Interest paid -3.4 -6.3 - -15.8 -26.1 -
Cash flow from financing activities of continuing operations -34.1 -23.4 - -200.8 -396.8 -
Change in cash and cash equivalents of continuing operations 36.5 25.8 42% 8.3 -115.9 -
Change in cash and cash equivalents of discontinued operations 0.9 -1.0 _ -1.5 -5.3 -
Change in value of cash and cash equivalents due to changes in foreign exchange rates 1.0 0.2 336% -3.2 1.9 -
Change in cash and cash equivalents 38.4 25.0 53% 3.6 -119.3 -
Cash and cash equivalents at January 1 / April 1 430.2 394.1 9% 465.0 538.4 -14%
Change in cash and cash equivalents of assets classified as held for sale 0.0 0.0 - 0.0 0.0 -
Cash and cash equivalents at June 30 468.6 419.1 12% 468.6 419.1 12%

1 Purchase price for acquisitions

Share buyback: As per September 30, 2025 a total of 532,307 have been purchased

{28}------------------------------------------------

Capital Allocation

1) Dividend Policy: payout ratio between 40 and 60% of adjusted net profit and continuous growth

{29}------------------------------------------------

Your Bilfinger IR Team

Director Investor Relations Phone: +49 (0) 69 / 580020-015 [email protected]

Director Group Investor Relations External Reporting Phone: +49 (0) 621 / 459-2455 [email protected]

Manager Investor Relations Phone: +49 (0) 621 / 459-3880 [email protected]

Jasmin Dentz Sascha Bamberger Nicola Bursitzky Maximilian H. W. Zabel

Manager Investor Relations Phone: +49 (0) 621 / 459-2486 [email protected]

Financial calendar

December 2, 2025 – Capital Markets Day 2025

March 4, 2026 – Publication of Annual financial statements 2025

May 13, 2026 – Quarterly Statement Q1 2026

May 20, 2026 – Annual General Meeting

August 12, 2026 – Quarterly Statement Q2 2026

November 11, 2026 – Quarterly Statement Q3 2026

{30}------------------------------------------------

Disclaimer

This document contains forward-looking statements, which are predictions, projections or other statements about future events. Such statements are based on plans, expectations, forecasts and assumptions as they are currently available to Bilfinger's management. Forward-looking statements and information speak only as of the date they are made, and Bilfinger neither intends nor assumes any obligation to update publicly or revise these forward-looking statements in light of future events or developments which differ from those anticipated. By their nature, forward-looking statements are subject to risks and uncertainties, including a negative change in market conditions, events of force majeure or changes in laws, regulations and government policies. A variety of such factors, many of which are beyond Bilfinger's control, could cause actual results, performance figures or events to differ significantly from those expressed or implied in the forward-looking statements.

The information contained in this document may comprise financial and similar information which is neither audited nor reviewed and should be considered preliminary and subject to change. It may also include data provided by third parties. Any such data is taken or derived from information published by sources that Bilfinger believes to be credible. Bilfinger has not independently verified the third-party data and makes no warranties as to its accuracy or completeness.

Due to rounding, numbers presented throughout this document may not add up in all cases precisely to the totals provided and percentages may not precisely reflect the absolute figures.

This document is being presented solely for informational purposes and does not constitute any form of investment advice or an offer or invitation to subscribe for or purchase any securities.

{31}------------------------------------------------

Your Performance Is Our Business

Talk to a Data Expert

Have a question? We'll get back to you promptly.